New research reveals that many patients with low-risk thyroid cancer can safely skip postoperative radioiodine ablation, ...

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous ...

A digital app significantly enhances the quality of life for caregivers of stem cell transplant patients, reducing stress and ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, ...

A multidisciplinary expert panel issued recommendations on the use of bronchoscopic biopsies in terms of safety and sample ...

A new drug for low-risk MDS is showing a surprising benefit: it's not just improving quality of life, but also extending patients' lives.

Manero, MD, discusses findings from the phase 3 COMMANDS trial evaluating luspatercept in patients with myelodysplastic ...

Panelist discusses how genetic testing is recommended for all patients with pancreatic adenocarcinoma at diagnosis, including ...

New long-term data from the COMMANDS trial reveals that luspatercept significantly prolongs survival for patients with low-risk MDS.

New trial results reveal that pembrolizumab and enfortumab vedotin significantly enhance survival rates for muscle-invasive ...

New research reveals that combining talazoparib with enzalutamide significantly enhances survival rates in metastatic ...